文献速递消化系统肿瘤

病毒状态对接受索拉非尼治疗的晚期肝细胞癌患者生存的影响:随机III期试验的荟萃分析

Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials.
PubMed 文献 · J Clin Oncol · 2017-01-03

该研究对三项大型前瞻性随机试验中接受索拉非尼治疗的1643例晚期肝细胞癌患者进行个体患者数据荟萃分析,采用贝叶斯分层分段指数模型。结果显示,在乙型肝炎病毒阴性且丙型肝炎病毒阳性的患者中,索拉非尼较其他治疗改善总生存(对数风险比-0.27,95%CI -0.46至-0.06),中位未调整生存12.6个月 vs 10.2个月;其他病毒状态亚组未见总生存改善证据。

要点

  • 在HBV阴性且HCV阳性的晚期肝细胞癌患者中,索拉非尼较其他治疗改善总生存。
  • 该亚组中位未调整生存:索拉非尼12.6个月 vs 其他治疗10.2个月。
  • 其他HBV/HCV状态亚组未见索拉非尼改善总生存的证据。

核心结论

  • 有 consistent 证据表明索拉非尼对总生存的影响取决于患者的肝炎状态。
  • HBV阴性且HCV阳性的患者接受索拉非尼治疗总生存改善。
  • HBV阳性且HCV阴性的患者未见索拉非尼归因的总生存改善证据。

研究设计与样本

  • 三项大型前瞻性随机III期试验中索拉非尼为对照组的个体患者数据荟萃分析。
  • 共3256例患者中,1643例(50%)接受索拉非尼者纳入分析。
  • 主要终点为总生存,采用贝叶斯分层个体患者数据荟萃分析的分段指数模型。

主要发现

  • HBV阴性且HCV阳性患者中,索拉非尼较其他治疗改善总生存(对数风险比-0.27,95%CI -0.46至-0.06)。
  • 该亚组中位未调整生存:索拉非尼12.6个月(95%CI 11.15至13.8) vs 其他治疗10.2个月(95%CI 8.88至12.2)。
  • 按HBV和HCV状态定义的其他患者亚组均未见总生存改善证据。
  • 结果在所有试验中一致,异质性采用Cochran Q统计量评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Following the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial, sorafenib has become the standard of care for patients with advanced unresectable hepatocellular carcinoma, but the relation between survival advantage and disease etiology remains unclear. To address this, we undertook an individual patient data meta-analysis of three large prospective randomized trials in which sorafenib was the control arm. Methods Of a total of 3,256 patients, 1,643 (50%) who received sorafenib were available. The primary end point was overall survival (OS). A Bayesian hierarchical approach for individual patient data meta-analyses was applied using a piecewise exponential model. Results are presented in terms of hazard ratios comparing sorafenib with alternative therapies according to hepatitis C virus (HCV) or hepatitis B virus (HBV) status. Results Hazard ratios show improved OS for sorafenib in patients who are both HBV negative and HCV positive (log [hazard ratio], -0.27; 95% CI, -0.46 to -0.06). Median unadjusted survival is 12.6 (11.15 to 13.8) months for sorafenib and 10.2 (8.88 to 12.2) months for "other" treatments in this subgroup. There was no evidence of improvement in OS for any other patient subgroups defined by HBV and HCV. Results were consistent across all trials with heterogeneity assessed using Cochran's Q statistic. Conclusion There is consistent evidence that the effect of sorafenib on OS is dependent on patients' hepatitis status. There is an improved OS for patients negative for HBV and positive for HCV when treated with sorafenib. There was no evidence of any improvement in OS attributable to sorafenib for patients positive for HBV and negative for HCV.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Jackson R, Psarelli EE, Berhane S, et al. Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials. J Clin Oncol. 2017. PMID: 28045619. doi:10.1200/JCO.2016.69.5197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。